|Bid||0.0000 x 3100|
|Ask||0.0000 x 4000|
|Day's Range||3.4900 - 3.7300|
|52 Week Range||2.5000 - 4.6800|
|Beta (5Y Monthly)||0.86|
|PE Ratio (TTM)||12.83|
|Earnings Date||Mar 08, 2022 - Mar 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.71|
Subscribe to Yahoo Finance Plus to view Fair Value for BDSILearn more
Shares of the small pharmaceutical company, which focuses on pain management, have been rising since it released updated guidance late last week.
BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance.
Total 2021 Net Revenue expected in the range of $165 -$167 million, as compared to previous guidance of $162-$167 million BELBUCA 2021 Net Sales expected to be in the range of $147 -$148 million, as compared to previous guidance of $144-$148 million 2021 EBITDA expected to be in the $40 - $45 million range as compared with previous guidance of <$40 million RALEIGH, N.C., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical